Back to Trials
NCT06220864PHASE1Recruiting

SNV1521 in Participants With Advanced Solid Tumors

Synnovation Therapeutics, Inc.

Start Date

2/23/2024

Completion Date

12/1/2027

Summary

This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Advanced or metastatic solid tumor malignancy * Evaluable or Measurable disease (RECIST 1.1 Criteria). * ECOG Performance Status 0 or 1. * Life expectancy \> 3 months Exclusion Criteria: * History of other malignancy within the past 2 years * Prior diagnosis of Myelodysplastic syndrome or Acute Myeloid Leukemia * Significant cardiovascular disease within 6 months * Significant gastrointestinal disease * HIV infection with a CD4+ T-cell count \< 200 cells/μL and/or a detectable viral load * Liver dysfunction

Interventions

DRUG

SNV1521

DRUG

DB-1310

DRUG

Abiraterone

DRUG

Darolutamide

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Advanced Solid Tumor

Locations

Smilow Cancer Hospital at Yale New Haven

New Haven, Connecticut 06511

United States

Thomas Jefferson University

Philadelphia, Pennsylvania 19144

United States

Sarah Cannon Research Institute

Nashville, Tennessee 37203

United States

The University of Texas M.D. Anderson Cancer Center

Houston, Texas 77030

United States

START Center for Cancer Care

West Valley City, Utah 84119

United States

Scientia Clinical Research

Randwick, New South Wales 2031

Australia

Princess Alexandra Hospital

Woolloongabba, Queensland 4102

Australia

Monash Health

Clayton, Victoria 3168

Australia

The Alfred Hospital

Melbourne, Victoria 3004

Australia

Linear Clinical Research

Crawley, Western Australia 6009

Australia

The Institut Jules Bordet

Brussels, 1070

Belgium

University Center for Clinical Research Antwerp (UNICCRA)

Edegem, 2650

Belgium

AZ Maria Middelares

Ghent, 9000

Belgium

AZ Groeninge

Kortrijk, 8500

Belgium

Arthur J.E. Child Comprehensive Cancer Centre

Calgary, Alberta T2N 5G2

Canada

Princess Margaret Hospital

Toronto, Ontario M5G 2M9

Canada

Institut Bergonie

Bordeaux, 33076

France

UNICANCER - Centre Leon-Berard (CLB)

Lyon, 69008

France

Gustave Roussy

Villejuif, 94805

France

Istituto Clinico Humanitas

Milan, 20089

Italy

Istituto Europeo di Oncologia (IEO) (European Institute of Oncology)

Milan, 20141

Italy

NEXT Oncology - Barcelona

Barcelona, 08023

Spain

Vall d'Hebron University Hospital

Barcelona, 08035

Spain

The START Center for Cancer Care - Madrid - CIOCC - Hospital Universitario Madrid Sanchinarro

Madrid, 28050

Spain

NEXT Oncology - Hospital Quironsalud Madrid

Madrid, 28223

Spain